Lenalidomide revenue decline sharper than expected
Lenalidomide sales expected to drop significantly after Q2 FY26; magnitude depends on pricing and competitor behavior.
DRREDDY / Q1-FY26 / risks
Keep the risk register visible.
Dr. Reddy's Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Semaglutide launch delays due to IP or regulatory hurdles
Canadian launch contingent on patent litigation outcome in India and FDA approval; any delay could push revenue to later quarters.
US generic price erosion persists
Base US business faces ongoing price erosion; management expects flat to single-digit growth but uncertainty remains.
SG&A costs may remain elevated
SG&A at 30% of sales in Q1; management targets 28-29% for full year, but NRT and nutraceutical investments could keep it higher.